Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from Chardan Capital

Key Points

• Krystal Biotech's stock has been given a "buy" rating by Chardan Capital, with a price target of $219.00, indicating a potential upside of 62.29% from its previous close.
• The company's latest earnings report showed an EPS of $1.29, outperforming analyst expectations of $1.08, alongside a revenue of $96.04 million.
• Institutional investors hold 86.29% of Krystal Biotech's stock, with notable recent increases in positions from firms like LPL Financial and JPMorgan Chase.

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $219.00 price objective on the stock. Chardan Capital's target price indicates a potential upside of 60.91% from the company's current price.

Several other brokerages have also weighed in on KRYS. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, July 25th. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Guggenheim cut their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating and set a $176.00 price objective (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $210.22.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded up $0.10 during trading hours on Tuesday, hitting $136.10. 320,029 shares of the company's stock traded hands, compared to its average volume of 418,876. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $207.84. The company's fifty day simple moving average is $141.71 and its two-hundred day simple moving average is $155.45. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 27.66 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, analysts anticipate that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 over the last 90 days. Company insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. S Squared Technology LLC boosted its stake in Krystal Biotech by 12.3% during the second quarter. S Squared Technology LLC now owns 109,215 shares of the company's stock worth $15,013,000 after buying an additional 12,000 shares in the last quarter. Profund Advisors LLC boosted its stake in Krystal Biotech by 36.9% during the second quarter. Profund Advisors LLC now owns 8,166 shares of the company's stock worth $1,122,000 after buying an additional 2,203 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in Krystal Biotech by 28.5% during the second quarter. Sound View Wealth Advisors Group LLC now owns 1,947 shares of the company's stock worth $268,000 after buying an additional 432 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Krystal Biotech during the second quarter worth $274,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Krystal Biotech by 20.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,795 shares of the company's stock valued at $247,000 after purchasing an additional 303 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).